Flecainide
Flecainide is a medicine taken by mouth, sold as flecainide acetate, that the US label describes as an antiarrhythmic drug, a medicine for heart rhythm problems. The label read, a generic tablet label, lists for people without structural heart disease the prevention of paroxysmal supraventricular tachycardias and of paroxysmal atrial fibrillation or flutter that cause disabling symptoms. It also lists the prevention of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that a physician judges to be life-threatening. The label says there is no evidence from controlled trials that the medicine favorably affects survival or the incidence of sudden death. It carries a boxed warning about an excess of deaths or non-fatal cardiac arrests in a trial of people who had had a heart attack.
Also called Tambocor
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 4441 (flecainide); the label names the salt flecainide acetate (RxNorm 42686, UNII M8U465Q1WQ, a broad match to the ingredient). MeSH descriptor D005424 is Flecainide. RxClass lists the FDA established pharmacologic class Antiarrhythmic. The label read is the Hikma Pharmaceuticals USA Inc. generic flecainide acetate tablet label, application ANDA076278, effective 2024-12-04 in openFDA; it is the only active ingredient of the product. The brand Tambocor (NDA018830) is listed in Drugs@FDA with marketing status Discontinued, and the openFDA name search for it returned no record, so no brand label was read. The other 34 openFDA flecainide labels, from manufacturers and repackagers, were not read. This page records label indications, the class, the mechanism sentence and the boxed warning on mortality only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says flecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents, with electrophysiologic effects characteristic of the IC class.
Classification codes
-
M8U465Q1WQFlecainide acetate
Claims and evidence
Context Patients with asymptomatic non-life-threatening ventricular arrhythmias after a myocardial infarction, as described in a US flecainide label boxed warning
- Recipient
- Recipient not specified
- Population
- The patients of the trial known as Cardiac Arrhythmia Suppression Trial (CAST), as the boxed warning describes them: patients with asymptomatic non-life-threatening ventricular arrhythmias who had a myocardial infarction more than six days but less than two years earlier. The warning says how far its results apply to other groups is uncertain. The passages read give no age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Patients with asymptomatic non-life-threatening ventricular arrhythmias who had a myocardial infarction more than six days but less than two years earlier (the trial population the warning describes)
- Excluded
- None stated
The same US label carries a boxed warning on mortality. It describes the trial known as Cardiac Arrhythmia Suppression Trial (CAST), in patients with asymptomatic non-life-threatening ventricular arrhythmias who had a myocardial infarction more than six days but less than two years earlier, and says an excessive mortality or non-fatal cardiac arrest rate was seen in patients treated with flecainide acetate compared with a matched placebo group.
Applies to Recipient not specified Patients with asymptomatic non-life-threatening ventricular arrhythmias after a myocardial infarction, as described in a US flecainide label boxed warning
- Certainty method
- Not assessed
- Limitations
- This claim records the first statement of the label's boxed warning only. The warning goes on to give the trial's numbers, to say how far the results apply to other populations, and to describe ventricular proarrhythmic effects in atrial fibrillation or flutter; those parts are not repeated here. Other warnings, contraindications and interactions were not recorded, and no instruction is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].boxed_warning[0], Mortality, trial population
- How it applies
- Label passage quoted in the research quote table (LB-12).
- Retrieved
- Source effective date
- 2024-12-04
- Source state
- Current
- Version fingerprint
f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], Mortality, finding
- How it applies
- Label passage quoted in the research quote table (LB-13).
- Retrieved
- Source effective date
- 2024-12-04
- Source state
- Current
- Version fingerprint
f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], Mortality, comparison
- How it applies
- Label passage quoted in the research quote table (LB-14).
- Retrieved
- Source effective date
- 2024-12-04
- Source state
- Current
- Version fingerprint
f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20241204.
- Retrieved
- Source effective date
- 2024-12-04
- Source state
- Current
- Version fingerprint
f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context Patients with paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation or flutter, or life-threatening ventricular arrhythmias, as described in the US label of flecainide acetate tablets
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label: patients without structural heart disease who have paroxysmal supraventricular tachycardias or paroxysmal atrial fibrillation or flutter with disabling symptoms, and patients with documented life-threatening ventricular arrhythmias. The passages read do not state an age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
- Included
- Patients without structural heart disease with paroxysmal supraventricular tachycardias associated with disabling symptoms
- Patients without structural heart disease with paroxysmal atrial fibrillation or flutter associated with disabling symptoms
- Patients with documented ventricular arrhythmias, such as sustained ventricular tachycardia, that are life-threatening in the physician's judgment
- Excluded
- None stated
The US label of flecainide acetate tablets (Hikma Pharmaceuticals USA Inc., application ANDA076278; the version dated 2024-12-04 in openFDA) describes flecainide as an antiarrhythmic drug. For patients without structural heart disease it lists prevention of paroxysmal supraventricular tachycardias, including atrioventricular nodal reentrant tachycardia, and of paroxysmal atrial fibrillation or flutter, each when associated with disabling symptoms. It also lists prevention of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the physician's judgment are life-threatening. It states that there is no evidence from controlled trials that flecainide acetate favorably affects survival or the incidence of sudden death.
Applies to Recipient not specified Patients with paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation or flutter, or life-threatening ventricular arrhythmias, as described in the US label of flecainide acetate tablets
- Certainty method
- Not assessed
- Limitations
- This claim records what one US generic label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label's indications section also carries usage statements on chronic atrial fibrillation and on where treatment for sustained ventricular tachycardia begins; they are not recorded here. Contraindications, other warnings, interactions, the label's pediatric statement and dosing were not recorded. The brand label (Tambocor) was not read, and openFDA lists other flecainide labels with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (7)
-
- Locator
- results[0].description[0], first sentence
- How it applies
- Label passage quoted in the research quote table (LB-04).
- Retrieved
- Source effective date
- 2024-12-04
- Source state
- Current
- Version fingerprint
f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], indications statement
- How it applies
- Label passage quoted in the research quote table (LB-05).
- Retrieved
- Source effective date
- 2024-12-04
- Source state
- Current
- Version fingerprint
f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], first bullet
- How it applies
- Label passage quoted in the research quote table (LB-06).
- Retrieved
- Source effective date
- 2024-12-04
- Source state
- Current
- Version fingerprint
f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], second bullet
- How it applies
- Label passage quoted in the research quote table (LB-07).
- Retrieved
- Source effective date
- 2024-12-04
- Source state
- Current
- Version fingerprint
f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], also-indicated bullet
- How it applies
- Label passage quoted in the research quote table (LB-08).
- Retrieved
- Source effective date
- 2024-12-04
- Source state
- Current
- Version fingerprint
f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], survival sentence
- How it applies
- Label passage quoted in the research quote table (LB-09).
- Retrieved
- Source effective date
- 2024-12-04
- Source state
- Current
- Version fingerprint
f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20241204.
- Retrieved
- Source effective date
- 2024-12-04
- Source state
- Current
- Version fingerprint
f169ac8e79f139426e76dcb5278599bb8cc2e1e156a79e94b6bda011fed49d78- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists prevention of paroxysmal supraventricular tachycardias associated with disabling symptoms, in patients without structural heart disease, as an indication: Supraventricular tachycardia
Applies to Recipient not specified Patients with paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation or flutter, or life-threatening ventricular arrhythmias, as described in the US label of flecainide acetate tablets
The US label of flecainide acetate tablets (Hikma Pharmaceuticals USA Inc., application ANDA076278; the version dated 2024-12-04 in openFDA) describes flecainide as an antiarrhythmic drug. For patients without structural heart disease it lists prevention of paroxysmal supraventricular tachycardias, including atrioventricular nodal reentrant tachycardia, and of paroxysmal atrial fibrillation or flutter, each when associated with disabling symptoms. It also lists prevention of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the physician's judgment are life-threatening. It states that there is no evidence from controlled trials that flecainide acetate favorably affects survival or the incidence of sudden death.Limitations. This claim records what one US generic label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label's indications section also carries usage statements on chronic atrial fibrillation and on where treatment for sustained ventricular tachycardia begins; they are not recorded here. Contraindications, other warnings, interactions, the label's pediatric statement and dosing were not recorded. The brand label (Tambocor) was not read, and openFDA lists other flecainide labels with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists prevention of paroxysmal atrial fibrillation or flutter associated with disabling symptoms, in patients without structural heart disease, as an indication: Atrial fibrillation (AF)
Applies to Recipient not specified Patients with paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation or flutter, or life-threatening ventricular arrhythmias, as described in the US label of flecainide acetate tablets
The US label of flecainide acetate tablets (Hikma Pharmaceuticals USA Inc., application ANDA076278; the version dated 2024-12-04 in openFDA) describes flecainide as an antiarrhythmic drug. For patients without structural heart disease it lists prevention of paroxysmal supraventricular tachycardias, including atrioventricular nodal reentrant tachycardia, and of paroxysmal atrial fibrillation or flutter, each when associated with disabling symptoms. It also lists prevention of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the physician's judgment are life-threatening. It states that there is no evidence from controlled trials that flecainide acetate favorably affects survival or the incidence of sudden death.Limitations. This claim records what one US generic label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label's indications section also carries usage statements on chronic atrial fibrillation and on where treatment for sustained ventricular tachycardia begins; they are not recorded here. Contraindications, other warnings, interactions, the label's pediatric statement and dosing were not recorded. The brand label (Tambocor) was not read, and openFDA lists other flecainide labels with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists prevention of paroxysmal atrial fibrillation or flutter associated with disabling symptoms, in patients without structural heart disease, as an indication: Atrial flutter
Applies to Recipient not specified Patients with paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation or flutter, or life-threatening ventricular arrhythmias, as described in the US label of flecainide acetate tablets
The US label of flecainide acetate tablets (Hikma Pharmaceuticals USA Inc., application ANDA076278; the version dated 2024-12-04 in openFDA) describes flecainide as an antiarrhythmic drug. For patients without structural heart disease it lists prevention of paroxysmal supraventricular tachycardias, including atrioventricular nodal reentrant tachycardia, and of paroxysmal atrial fibrillation or flutter, each when associated with disabling symptoms. It also lists prevention of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the physician's judgment are life-threatening. It states that there is no evidence from controlled trials that flecainide acetate favorably affects survival or the incidence of sudden death.Limitations. This claim records what one US generic label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label's indications section also carries usage statements on chronic atrial fibrillation and on where treatment for sustained ventricular tachycardia begins; they are not recorded here. Contraindications, other warnings, interactions, the label's pediatric statement and dosing were not recorded. The brand label (Tambocor) was not read, and openFDA lists other flecainide labels with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists prevention of documented life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia, as an indication: Ventricular tachycardia
Applies to Recipient not specified Patients with paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation or flutter, or life-threatening ventricular arrhythmias, as described in the US label of flecainide acetate tablets
The US label of flecainide acetate tablets (Hikma Pharmaceuticals USA Inc., application ANDA076278; the version dated 2024-12-04 in openFDA) describes flecainide as an antiarrhythmic drug. For patients without structural heart disease it lists prevention of paroxysmal supraventricular tachycardias, including atrioventricular nodal reentrant tachycardia, and of paroxysmal atrial fibrillation or flutter, each when associated with disabling symptoms. It also lists prevention of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the physician's judgment are life-threatening. It states that there is no evidence from controlled trials that flecainide acetate favorably affects survival or the incidence of sudden death.Limitations. This claim records what one US generic label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label's indications section also carries usage statements on chronic atrial fibrillation and on where treatment for sustained ventricular tachycardia begins; they are not recorded here. Contraindications, other warnings, interactions, the label's pediatric statement and dosing were not recorded. The brand label (Tambocor) was not read, and openFDA lists other flecainide labels with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:flecainide- Content hash
879f0366a909366cbcffbad1f6d58a31d5b6c5b3feaab4314b162b8ecfed2abd